Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

DISEASE CHARACTERISTICS: * Histologically proven chronic myelogenous leukemia * Must have (9;22) translocation or bcr/abl transcript, and b3a2 breakpoint * No accelerated or blastic phase * Must be in hematologic remission with peripheral WBC less than 20,000/mm\^3 PATIENT CHARACTERISTICS: Age: * Over 16 Performance status: * Karnofsky 70-100% Life expectancy: * Not specified Hematopoietic: * See Disease Characteristics * Absolute granulocyte count greater than 1,200/mm\^3 * Platelet count greater than 70,000/mm\^3 * Hemoglobin greater than 9.0 g/dL * No active bleeding Hepatic: * Bilirubin less than 2.0 mg/dL * Lactate dehydrogenase less than 2 times normal Renal: * Creatinine less than 2.0 mg/dL Cardiovascular: * No New York Heart Association class III or IV heart disease Other: * No uncontrolled active infection requiring antibiotics * No other serious illness * No immunodeficiency other than from prior bone marrow transplantation * Not pregnant or nursing PRIOR CONCURRENT THERAPY: Biologic therapy: * At least 6 months since prior allogeneic or autologous bone marrow transplantation * Prior vaccination with pentavalent peptide at less than study dose level allowed * At least 4 weeks since prior immunotherapy other than interferon, donor lymphocyte infusion, or pentavalent vaccine * Concurrent interferon allowed Chemotherapy: * At least 2 weeks since prior low-dose subcutaneous cytarabine * At least 4 weeks since prior chemotherapy other than hydroxyurea * No concurrent chemotherapy except hydroxyurea Endocrine therapy: * No concurrent corticosteroids Radiotherapy: * At least 4 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * No concurrent surgery Other: * Concurrent imatinib mesylate allowed * No other concurrent systemic therapy